Introduction: We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC.
Introduction
Small molecule EGFR tyrosine kinase inhibitors (TKIs) are a highly effective treatment for advanced NSCLC with activating mutations of the EGFR gene. Despite an initial response, most of these patients experience disease progression approximately 10 to 13 months after first-line TKI therapy. Selection of optimal salvage therapy for some of these patients remains an ongoing challenge.
Several mechanisms of acquired resistance to TKI therapy have been reported: new EGFR T790M mutation, 1, 2 transformation to a small cell histological type, 1 and activation of alternative antiapoptosis signaling pathways. [1] [2] [3] [4] Third-generation TKIs are potent oral irreversible inhibitors of sensitizing EGFR mutations and the T790M resistance mutation. Third-generation TKIs can be effective salvage therapy for patients in whom T790M mutation develops and whose disease progresses during treatment with earlier-generation TKIs. 5 Novel immunotherapy agents, nivolumab 6 and pembrolizumab, 7 which are programmed death 1 (PD-1) immune checkpoint inhibitors, are potential alternative salvage treatments. Both prolong overall survival (OS) compared with docetaxel and have been approved by the U.S. Food and Drug Administration as a new standard of care for second-line treatment of advanced NSCLC.
Evidence to support the role of immune checkpoint inhibitors in EGFR-mutated lung cancers is conflicting. Murine models have demonstrated significant response to the treatment with anti-PD-1 antibody in EGFRmutant but not KRAS-driven lung tumors 8 ; however, in a retrospective analysis of 58 patients with advanced NSCLC treated with PD-1/programmed death ligand 1 (PD-L1) inhibitors, only 4% of patients harboring EGFR mutations or anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements were tumor responders and 23% of patients with EGFR wild-type and ALK-negative or unknown tumors were responders. 9 We performed this meta-analysis to better assess the role of immune checkpoint inhibitors in EGFR-mutated advanced NSCLC.
Methods
Eligible randomized trials that compared immune checkpoint inhibitors against chemotherapy in the second-line setting were identified from MEDLINE, EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials databases for articles published in English between January 1996 and July 2016 by using the following terms: advanced/metastatic lung neoplasm/cancer/carcinoma, checkpoint inhibitor, cytotoxic T-lymphocyte associated protein 4, PD-1, PD-L1, ipilimumab, nivolumab, pembrolizumab, and randomized/controlled clinical trial. To identify unpublished studies, we also searched abstracts from proceedings of the American Society of Clinical Oncology and European Society for Medical Oncology conferences and proceedings of the World Lung Cancer Conference.
For each included trial, we extracted study and patient characteristics and retrieved the hazard ratio (HR) and 95% confidence interval (CI) for OS of the intentionto-treat population and subgroups defined by EGFR mutation status. Data were extracted independently by two authors (C. L. and J. M.), with discrepancies resolved by consensus.
We used the fixed-effects inverse variance-weighted method to pool results to estimate the size of the benefit of treatment. A test for treatment-mutation interaction was used to assess differences in treatment effect across EGFRdefined subgroups. All statistical tests were two sided.
Results
We identified three eligible trials 6, 7, 10, 11 (Table 1 and Fig. 1 
Discussion
In this hypothesis-generating study, meta-analysis has demonstrated that EGFR mutation status is a potential predictive biomarker for OS in advanced NSCLC treated with an immune checkpoint inhibitor versus with docetaxel. There was no OS advantage in the EGFR-mutant subgroup, but there was a 34% reduction in the risk for death in the EGFR wild-type subgroup. Reliable biomarkers that could be used to select patients with a higher likelihood of benefit from immune checkpoint inhibitors remain vital in second-line treatment of advanced NSCLC. EGFR mutation has not been examined as a biomarker for this purpose. Current research has focused on PD-L1 overexpression as a predictive biomarker for checkpoint inhibition. 6, [10] [11] [12] In one study of patients with PD-L1 overexpression, defined as PD-L1 expression in more than 50% of tumor cells (i.e., tumor proportional score [TPS] > 50%), patients with EGFR-mutant tumors had significantly shorter OS than those who had EGFR wild-type tumors (median OS ¼ 6.5 vs. 15.7 months) when treated with pembrolizumab. 12 In fact, OS did not differ significantly according to PD-L1 expression in the EGFR-mutant (TPS > 50% vs. <1%: median OS ¼ 6.5 vs. 5.7 months). In the EGFR wild-type subgroup (TPS > 50% vs. <1%: median OS ¼ 15.7 vs. 9.1 months). The predictive value of PD-L1 overexpression, particularly for the EGFR-mutant subgroup, remains unclear. Further, the concordance of PD-L1 expression with EGFR status and variation in PD-L1 expression with different types of EGFR mutations are also unknown. Another vital unanswered research question is whether the different mutations of the EGFR gene have different immunogenicity and hence result in different tumor responses to immune checkpoint inhibition.
Mutation burden in lung and other cancers is also considered predictive of benefit for checkpoint inhibition. Among patients with NSCLC treated with pembrolizumab, higher nonsynonymous mutation burden in tumors has been associated with greater clinical benefit. 13 Interestingly, EGFR-mutated lung cancer was shown to have low mutation burden in another study using next-generation sequencing, 14 providing a plausible biological explanation for the finding of our metaanalysis. Immunogenicity of EGFR-mutant tumors could be increased with combination treatments including PD-1 and cytotoxic T-lymphocyte associated protein 4 inhibitors, as demonstrated by significant response over that with PD-1 monotherapy (50% vs. 14%) in a small study. 15 Further trials are required to confirm this finding.
The major strength of this study is the inclusion of the most up-to-date data from all relevant trials, which overcomes the problem of inadequate power of individual trials to compare EGFR subgroups to assess a mutation-treatment interaction. The major limitation of our retrospective analysis is that EGFR status was not assessed in 19% of patients. We also acknowledge that the EGFR subgroup comprised only 186 patients and the different types of EGFR mutations were unknown.
Nevertheless, we believe that these data provide useful exploratory information. Other limitations are that EGFR status was not determined universally by means of centralized testing in the included studies. The number of lines of TKI therapies received and whether patients who received multiple lines were equally distributed between randomized arms was also unknown. The impact of these factors on our analyses is unknown. Given these limitations, prospectively designed and adequately powered randomized trials will be required to confirm the value of EGFR mutation to predict OS benefit with immune checkpoint inhibitor treatment over docetaxel.
Future research should compare, in a head-to-head randomized trial, a T790M inhibitor against a combination of different immune checkpoint inhibitors or a combination of an immune checkpoint inhibitor with a T790M inhibitor for the majority of patients who acquired a new EGFR T790M mutation 1,2 after progression from first-line TKI therapy. For those patients without T790M mutation or those who had a T790M mutation but progressed after T790M inhibitor therapy, the role of immune checkpoint agents also warrants further investigation.
In conclusion, an immune checkpoint inhibitor as second-line therapy did not improve OS over that with docetaxel therapy in EGFR-mutated advanced NSCLC. This finding should be considered as hypothesisgenerating and interpreted cautiously. For patients with EGFR-mutated advanced NSCLC, mechanisms of acquired resistance to first-line TKI therapy should be elucidated to guide second-line treatment selection.
